NMN (Nicotinamide Mononucleotide)
NMN (nicotinamide mononucleotide) is a naturally occurring molecule and direct precursor to NAD+, a coenzyme required for over 500 cellular reactions. NMN supplements are taken orally and converted to NAD+ in the body, raising NAD+ levels that decline with age. A 2021 study in Science showed NMN improved muscle insulin sensitivity in postmenopausal women, and multiple human trials confirm it safely elevates NAD+ levels.
FormBlends Peptide Context
Reviewed May 14, 2026Nmn peptide guide is most useful when it turns a vague health question into a better checklist. The page should clarify peptide therapy, then point the reader toward the details that matter in real care: labs, medications, contraindications, follow-up, and cost transparency.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
NMN authority snapshot
NMN is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Meaningful evidence with limits
Regulatory reality
Not affected (dietary supplement)
Safety screen
Generally well-tolerated at standard doses, Mild GI discomfort in some users, Flushing at higher doses should be reviewed in context.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for NMN?
NMN should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- NMN
- Category
- Anti-Aging
- Evidence
- Meaningful evidence with limits
- FDA status
- Not FDA approved
Step 1
Check evidence level
NMN has growing human evidence. The key study is a 2021 randomized controlled trial published in Science (N=25) showing improved muscle insulin sensitivity in postmenopausal prediabetic women after 10 weeks of 250 mg/day. A 2022 study in JCEM (N=30) confirmed safety and NAD+ elevation in healthy men. Multiple other small human trials are consistent. The evidence is moderate because the studies are small, but the direction is consistently positive.
Review evidenceStep 2
Screen safety context
Generally well-tolerated at standard doses, Mild GI discomfort in some users, Flushing at higher doses should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If this is research-only or not directly offered, compare clinic and provider routes before taking action.
Compare clinicsLast updated: April 6, 2026
Typical Dosage
250-500 mg orally once daily, typically in the morning. Some protocols use up to 1,000 mg/day.
Administration
Oral capsule, Sublingual tablet, Oral powder
Typical Cost
$30-100/month
FDA Status
Not FDA Approved
Half-Life
NMN itself has a short plasma half-life (minutes to hours), but the NAD+ it generates has longer-lasting effects on cellular metabolism.
Onset of Action
Blood NAD+ levels increase within hours of dosing. Sustained elevation with daily dosing over 1-2 weeks. Metabolic effects in the Science trial appeared at 10 weeks.
Bioavailability
Good oral bioavailability. Absorbed through the small intestine via the Slc12a8 transporter. Sublingual may offer faster absorption.
About NMN
NMN (nicotinamide mononucleotide) is a nucleotide derived from ribose and nicotinamide. Molecular weight: 334.22 Da. CAS number: 1094-61-7. It's one of the key precursors to NAD+ (nicotinamide adenine dinucleotide), the coenzyme that every cell needs for energy metabolism, DNA repair, and longevity signaling.
The reason NMN has attracted so much attention is straightforward. NAD+ levels decline clearally with age, and this decline is linked to virtually every aspect of biological aging: mitochondrial dysfunction, DNA damage accumulation, inflammation, and metabolic decline. If you can raise NAD+ levels back toward youthful ranges, the theory is that you can slow or reverse some of these processes.
The question is whether supplementation actually does this in humans. The answer, as of 2026, is a qualified yes.
The landmark human study was published in Science in 2021 (PMID: 33888596) by a team at Washington University in St. Louis. They gave 250 mg/day of NMN to 25 postmenopausal women with prediabetes for 10 weeks. The NMN group showed improved muscle insulin sensitivity and changes in muscle gene expression related to structural remodeling. This was the first human trial to show a meaningful clinical effect from NMN supplementation, not just elevated biomarkers.
A 2021 study in the Journal of the International Society of Sports Nutrition (PMID: 34238308) tested NMN at doses from 300 to 1,200 mg/day in amateur runners for 6 weeks and found improved aerobic capacity and oxygen utilization. A 2022 trial in JCEM (PMID: 35771659) confirmed that 250 mg/day for 12 weeks safely raised NAD+ metabolites in healthy overweight adults.
NMN vs NR (nicotinamide riboside) is a common question. Both are NAD+ precursors. NR was first to market and has a few more published human trials. NMN is one step closer to NAD+ in the biosynthetic pathway. In practice, both raise NAD+ levels effectively. NMN tends to be more expensive but some researchers believe it may be more efficiently converted. The honest answer is that no head-to-head trial has definitively shown one is better than the other.
The supplement industry around NMN is large and growing. Quality varies enormously between brands. Third-party testing (via companies like ChromaDex or Eurofins) is the best way to verify that a product contains what it claims. Look for certificates of analysis showing purity above 99% and absence of contaminants.
Store NMN in a cool, dry place away from heat and moisture. Some manufacturers recommend refrigeration for long-term storage. The powder form is hygroscopic (absorbs moisture from air), so keeping it sealed is important.
How NMN Works
NMN is transported into cells where it's converted to NAD+ by the enzyme NMNAT. NAD+ then fuels sirtuin enzymes (SIRT1-7) involved in DNA repair, mitochondrial function, and cellular stress response. It also powers PARP enzymes for DNA damage repair and supports the electron transport chain for cellular energy production. The age-related decline in NAD+ is linked to mitochondrial dysfunction, inflammation, and metabolic decline.
Receptor targets:
Benefits
- Raises NAD+ levels by 40-60% in human trials
- Improved muscle insulin sensitivity in a Science-published RCT
- Supports mitochondrial energy production
- Activates sirtuin enzymes involved in DNA repair and longevity pathways
- Orally bioavailable (unlike direct NAD+ supplementation)
- Well-tolerated in human safety studies up to 1,200 mg/day
- May support cardiovascular function through NAD+-dependent pathways
What Does the Research Say?
NMN has growing human evidence. The key study is a 2021 randomized controlled trial published in Science (N=25) showing improved muscle insulin sensitivity in postmenopausal prediabetic women after 10 weeks of 250 mg/day. A 2022 study in JCEM (N=30) confirmed safety and NAD+ elevation in healthy men. Multiple other small human trials are consistent. The evidence is moderate because the studies are small, but the direction is consistently positive.
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
10 weeks of 250 mg/day NMN improved muscle insulin sensitivity, insulin signaling, and muscle remodeling in 25 postmenopausal prediabetic women
PubMed evidence trail
Research sources used to frame this page
For NMN, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Potential Side Effects
- Generally well-tolerated at standard doses
- Mild GI discomfort in some users
- Flushing at higher doses
- Theoretical cancer concern (see interactions)
Drug Interactions
| Compound | Interaction | Severity |
|---|---|---|
| Cancer medications | NAD+ is used by rapidly dividing cells, including cancer cells. Some researchers advise against NMN supplementation during active cancer treatment. This is still debated, but the theoretical concern is real. | major |
Who Is NMN For?
Women
The most compelling human RCT (Science, 2021) was specifically conducted in postmenopausal women and showed improved insulin sensitivity. This is a well-studied population for NMN.
Adults Over 50
The primary target demographic. NAD+ levels decline roughly 50% between ages 40 and 60. Most longevity-focused NMN users are over 40.
Athletes
Not banned by WADA. The 2021 sports nutrition study showed improved aerobic capacity at 300-1200 mg/day in amateur runners.
Regulatory Status
FDA Approved
No
Compounding Legal
Yes
2026 HHS Status
Not affected (dietary supplement)
Available as a dietary supplement without prescription. The FDA temporarily questioned NMN's supplement status in late 2022 after a drug company filed an IND, but enforcement action was not taken and NMN supplements remain widely sold as of 2026.
Last verified: 2026-04-06
Stacking Options
NMN is commonly stacked with the following peptides for enhanced results:
Conditions Addressed
Find a NMN Clinic Near You
Browse peptide therapy clinics in your area that offer nmn treatments.
Find Peptide Clinics